Citation

Prüter C, Norra C. Nervenheilkd. 2002; 21(7): 372-378.

Copyright

(Copyright © 2002, Georg Thieme Verlag)

DOI

unavailable

PMID

unavailable

Abstract

Depressive disorders often remain unrecognized and untreated in patients with epilepsy, however the relatively high prevalence and the high incidence of suicides point towards the necessity for diagnosis and proper treatment. In epilepsy the clinical picture of depressive syndromes usually does not meet the ICD-10 or DSM-IV criteria of the affective disorders. The reported incidence for depressive disorders in epilepsy varies between 30-70%. Various causative factors such as seizure type, lateralization of seizure focus, dysfunctions in neurotransmission as well as hereditary, psychosocial factors or negative psychotropic properties of antiepileptic drugs (AED), contribute to the pathogenesis. Despite the lack of controlled studies the administration of serotonergic antidepressants in the treatment of depressive disorders in epilepsy can be recommended.

Language: de

Keywords

amitriptyline; anticonvulsant therapy; anticonvulsive agent; antidepressant agent; Antidepressants; Antiepileptic drugs; carbamazepine; citalopram; clinical trial; clomipramine; comorbidity; controlled clinical trial; controlled study; depression; Depression; desipramine; double blind procedure; doxepin; drug efficacy; drug induced disease; drug safety; electroconvulsive therapy; electroencephalogram; epilepsy; Epilepsy; fluoxetine; fluvoxamine maleate; gabapentin; human; imipramine; lamotrigine; lofepramine; maprotiline; mental disease; mirtazapine; moclobemide; multicenter study; nefazodone; neurotransmission; nortriptyline; paroxetine; pathogenesis; phenobarbital; phenytoin; primidone; psychopharmacotherapy; psychotherapy; review; serotonin uptake inhibitor; sertraline; symptomatology; topiramate; trazodone; tricyclic antidepressant agent; unindexed drug; venlafaxine; viloxazine